EPIRUS Biopharmaceuticals Initiates Pivotal Global Phase 3 Clinical Study for BOW015 (Infliximab Biosimilar)
February 09, 2016 07:00 ET
|
EPIRUS Biopharmaceuticals, Inc.
UNIFORMi Study builds on prior successful Phase 1 and Phase 3 studiesIntended to support harmonized global filing for BOW015 in 2017BOW015 is a biosimilar for Remicade®, which had global sales of...